<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050136</url>
  </required_header>
  <id_info>
    <org_study_id>VLX-601</org_study_id>
    <nct_id>NCT05050136</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis</brief_title>
  <acronym>VANTAGE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn more about the use of the study&#xD;
      medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary&#xD;
      Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaire</measure>
    <time_frame>Baseline to week 28</time_frame>
    <description>The Adult ItchRO is an 11-point NRS measurement of itch severity ranging from 0=no itch to 10=worst possible itch.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with itch response using the Adult ItchRO</measure>
    <time_frame>Baseline to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Baseline to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in aspartate aminotransferase</measure>
    <time_frame>Baseline to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alanine aminotransferase</measure>
    <time_frame>Baseline to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alkaline phosphatase</measure>
    <time_frame>Baseline to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total bilirubin</measure>
    <time_frame>Baseline to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in direct bilirubin</measure>
    <time_frame>Baseline to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting serum bile acid levels</measure>
    <time_frame>Baseline to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Primary Biliary Cholangitis Quality of Life Measure (PBC-40)</measure>
    <time_frame>Baseline to week 28</time_frame>
    <description>PBC-40 questionnaire is scored on a scale of 40 to 200, with higher scores indicating poorer quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) fatigue questionnaire</measure>
    <time_frame>Baseline to week 28</time_frame>
    <description>The PROMIS® Fatigue questionnaire is a 5-point response scale. Respondents endorse each item using a 5-point response scale: Never, Rarely, Sometimes, Often, and Always.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) sleep disturbance questionnaire</measure>
    <time_frame>Baseline to week 28</time_frame>
    <description>The PROMIS® Sleep Disturbance in an 8-item measure that assesses quality of sleep, sleep depth, and restoration associated with sleep. It is a 5-point response scale, the specific response options vary by items. The first 4 items use response options that range from Not at all to Very much. The next 3 items use response options that range from Never to Always. The final item assesses sleep quality ranging from Very poor to Very good.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <condition>PBC</condition>
  <arm_group>
    <arm_group_label>Volixibat 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive volixibat 20mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volixibat 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive volixibat 80mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volixibat</intervention_name>
    <description>Oral capsules, administered twice daily. Volixibat is an apical sodium-dependent bile acid transporter (ASBT) inhibitor.</description>
    <arm_group_label>Volixibat 20mg</arm_group_label>
    <arm_group_label>Volixibat 80mg</arm_group_label>
    <other_name>SHP626</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules matched to study drug without the active pharmaceutical ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed informed consent at the screening visit as well as comply with all&#xD;
             study visits and requirements through the end of the study&#xD;
&#xD;
          -  Male or female, age ≥18 years at the screening visit&#xD;
&#xD;
          -  Confirmed diagnosis of PBC in line with the AASLD guidelines&#xD;
&#xD;
          -  UDCA and anti-pruritic medication use will be allowed if meeting additional criteria&#xD;
&#xD;
          -  Qualified pruritus associated with PBC as assessed by Adult ItchRO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pruritus associated with an etiology other than PBC&#xD;
&#xD;
          -  Evidence or clinical suspicion of decompensated cirrhosis or a history of&#xD;
             decompensation events&#xD;
&#xD;
          -  Current symptomatic cholelithiasis or inflammatory gallbladder disease&#xD;
&#xD;
          -  History of small bowel surgery/resection impacting the terminal ileum that may disrupt&#xD;
             the enterohepatic circulation.&#xD;
&#xD;
          -  Evidence, history, or suspicion of other liver diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasey Seyer</last_name>
      <phone>619-522-0330</phone>
      <phone_ext>122</phone_ext>
      <email>kasey@researchscrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Medina</last_name>
      <phone>305-243-4615</phone>
      <email>ejm202@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute, Inc</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Tyson</last_name>
      <phone>727-835-3261</phone>
      <email>christina.are@ariclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Covenant Research and Clinics, LLC</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Valle</last_name>
      <phone>941-500-3200</phone>
      <email>veronica.valle@covresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jackson Liver and GI Specialists</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stormee White</last_name>
      <phone>769-251-5674</phone>
      <email>Swhite@jacksonliverandgi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <keyword>PBC</keyword>
  <keyword>Itching</keyword>
  <keyword>Cholangitis</keyword>
  <keyword>Primary Biliary Cholangitis</keyword>
  <keyword>Hepatobiliary disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volixibat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

